Celcuity's phase 3 VIKTORIA-1 trial showed that gedatolisib significantly improved progression-free survival in PIK3CA wild-type HR+/HER2-advanced breast cancer patients. NDA submission for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback